Skip to content
QHQHQH202020& 25& 25& 25

Drawing based on the description in the official product monograph. No photo yet.

“20 / 25 mg: Contains 20 mg of quinapril (as quinapril hydrochloride) and 25 mg of hydrochlorothiazide and tablets are pink, round, biconvex, film coated tablet debossed with "QH" on one side and "20 & 25" on another side of tablet”

QH 20 & 25 pill

Pill with imprint QH 20 & 25 is pink, round and has been identified as Quinapril Hydrochloride and Hydrochlorothiazide 20 mg / 25 mg. It is used for high blood pressure. It is supplied by Jamp Pharma Corporation.

Sold in Canada

Quinapril Hydrochloride and Hydrochlorothiazide 20 mg / 25 mg

Brand
Jamp Quinapril / HCTZ
Imprint
QH 20 & 25
Strength
Quinapril Hydrochloride 20 mg / Hydrochlorothiazide 25 mg
Used for
High blood pressure
Color
Pink
Shape
Round
Form
Tablet
Manufacturer
Jamp Pharma Corporation
Drug class
ACE inhibitor (blood pressure and heart medicine)
Sold in
Canada
DIN
02547449

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Quinapril and Hydrochlorothiazide pills and guides

What is Quinapril and Hydrochlorothiazide used for?

Quinapril and Hydrochlorothiazide is used for high blood pressure.

Medicine type
ACE inhibitor (blood pressure and heart medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label

Hypertension: Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride and hydrochlorothiazide tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).

In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).

Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

From the FDA-approved label on DailyMed (published Jan 08, 2016).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows QH 20 & 25. The parts can be split between the two sides, so turn the pill over and check both.
  • It is pink, round.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Jamp Quinapril / HCTZ by Jamp Pharma Corporation.

In Canada: prescription only.

Ingredients

Active: Quinapril (Quinapril Hydrochloride), Hydrochlorothiazide

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Quinapril and Hydrochlorothiazide pills